{"entity":{"id":"moma-therapeutics","kind":"company","name":"MOMA Therapeutics","aka":[],"tldr":"MOMA Therapeutics makes tablets that block DNA repair machinery that some cancers depend on to survive. One medicine is for tumours with faulty BRCA-type repair, another for tumours with mismatch repair defects.","summary":"MOMA Therapeutics, based in Cambridge, Massachusetts, targets molecular machines, enzymes that work through stepwise changes in shape, and launched in 2020, according to the company. MOMA-313 is an oral inhibitor of the helicase domain of DNA polymerase theta (Pol theta), in a phase 1 trial (NCT06545942) alone and with olaparib in homologous recombination deficient solid tumours. MOMA-341 is an oral inhibitor of the Werner (WRN) helicase, in a phase 1 trial (NCT06974110) alone or with irinotecan or immunotherapy in MSI-high or mismatch repair deficient tumours, with a first patient dosed in July 2025. In January 2025 the company in-licensed a selective PARP1 inhibitor, MOMA-989, for development alone and with MOMA-313. It announced a discovery collaboration with Roche in January 2024 and a collaboration and licence agreement with Bayer in October 2024. It raised a 150 million US dollar Series B in May 2022 led by Goldman Sachs Asset Management. Its first registered cancer trial, NCT06545942, was posted on ClinicalTrials.gov in August 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://momatx.com/"},{"label":"Series B release, May 2022","url":"https://momatx.com/posts/moma-therapeutics-announces-150-million-series-b-financing/"},{"label":"Corporate update and PARP1 in-licence, January 2025","url":"https://momatx.com/posts/moma-therapeutics-provides-corporate-update-and-announces-exclusive-license-agreement-for-selective-parp1-inhibitor/"},{"label":"ClinicalTrials.gov: phase 1 trial of MOMA-313 (NCT06545942)","url":"https://clinicaltrials.gov/study/NCT06545942"},{"label":"ClinicalTrials.gov: phase 1 trial of MOMA-341 (NCT06974110)","url":"https://clinicaltrials.gov/study/NCT06974110"}],"tags":[],"related":[],"cancers":["msi-high-colorectal","endometrial-mmr-deficient"],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches","parp-inhibitor"],"targets":["polq","wrn"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year from the chief executive's statement 'since our launch in 2020' in the May 2022 Series B release, read on 29 October 2026.","The Series A amount was not read on a company source and is not recorded.","MOMA-989 IND timing was a plan in January 2025; whether it has entered the clinic was not checked."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://momatx.com/","founded":2020,"stage":"growth","investors":["third-rock-ventures","section-32","casdin-capital","cormorant-asset-management","alexandria-venture-investments"],"funding":[{"round":"Series B","year":2022,"amountUsd":150000000,"source":"https://momatx.com/posts/moma-therapeutics-announces-150-million-series-b-financing/","note":"Led by Goldman Sachs Asset Management with Section 32, Pavilion Capital, Invus and LifeSci Venture Partners; Series A investors including Third Rock Ventures, Casdin Capital, Cormorant Asset Management and Alexandria Venture Investments participated"}]},"route":"/companies/moma-therapeutics/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/"},{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/"}],"company":[{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/"},{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/"},{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/"},{"id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}]}}